SCHEMBL3190599

SCHEMBL3190599

OCCOCCOCCOCCOCCOCCOC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.55
DUT P33316 2/20 0.48
TK2 O00142 5/20 0.46
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.41
RECQL P46063 1/20 0.41
HRH4 Q9H3N8 1/20 0.40
TSHR P16473 2/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
ALOX15 P16050 1/20 0.38
SLC6A1 P30531 1/20 0.38
PPARG P37231 1/20 0.37
KCNH3 Q9ULD8 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
TK1 P04183 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26176904 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176883 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176911 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176881 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL24207815 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL24207971 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL4454711 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL2821674 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL3485522 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A
SCHEMBL26176900 1.00 KIF11 (0.55) KIF11DUTTK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 US disclosed
EP-4182296-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF Sanofi Pasteur (FR) 2023-05-24 EP disclosed
WO-2022013439-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2022-01-20 WO disclosed
US-10241234-B2 Silicone hydrogel soft contact lens having wettable surface HOYA CORPORATION (JP) 2019-03-26 US disclosed
US-9529119-B2 Method for fabricating silicone-containing copolymer molded article having hydrophilic surface and silicone-hydrogel contact lens having hydrophilic surface HOYA CORPORATION (JP) 2016-12-27 US disclosed
US-9529119-B2 Method for fabricating silicone-containing copolymer molded article having hydrophilic surface and silicone-hydrogel contact lens having hydrophilic surface HOYA CORPORATION (JP) 2016-12-27 US disclosed
US-20160282516-A1 METHOD FOR FABRICATING SILICONE-CONTAINING COPOLYMER MOLDED ARTICLE HAVING HYDROPHILIC SURFACE AND SILICONE-HYDROGEL CONTACT LENS HAVING HYDROPHILIC SURFACE HOYA CORPORATION (JP) 2016-09-29 US disclosed
US-20160282516-A1 METHOD FOR FABRICATING SILICONE-CONTAINING COPOLYMER MOLDED ARTICLE HAVING HYDROPHILIC SURFACE AND SILICONE-HYDROGEL CONTACT LENS HAVING HYDROPHILIC SURFACE HOYA CORPORATION (JP) 2016-09-29 US disclosed
WO-2012122144-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES WU NIAN (US) 2012-09-13 WO disclosed
US-20120232169-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES BIOZONE PHARMACEUTICALS, INC. (US) 2012-09-13 US disclosed
US-20120232169-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES BIOZONE PHARMACEUTICALS, INC. (US) 2012-09-13 US disclosed
US-20110040113-A1 Pure PEG-lipid conjugates WU NIAN 2011-02-17 US disclosed
US-20110040113-A1 Pure PEG-lipid conjugates WU NIAN 2011-02-17 US disclosed
US-7655768-B2 Galactose derivative, drug carrier and medicinal composition NIPPON SHINYAKU CO., LTD. (JP) 2010-02-02 US disclosed
US-20070244058-A1 Galactose Derivative, Drug Carrier and Medicinal Composition NIPPON SHINYAKU CO., LTD. (JP) 2007-10-18 US disclosed
EP-1783137-A1 GALACTOSE DERIVATIVE, DRUG CARRIER AND MEDICINAL COMPOSITION Nippon Shinyaku Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-0540612-A1 HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES Pharmacia AB (SE) 1993-05-12 EP disclosed
WO-1992001474-A1 HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES KABI PHARMACIA AB (SE) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF MTTP, CETP, LNPEP KIF11 2133/4885DUT 669/4885TK2 2315/4885
US-20120232169-A1 HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES LIPA, CETP, DGAT2 KIF11 417/4885DUT 422/4885TK2 1335/4885
US-20110040113-A1 Pure PEG-lipid conjugates DGAT2, MGLL, DGAT1 KIF11 675/4885DUT 763/4885TK2 2220/4885
US-20070244058-A1 Galactose Derivative, Drug Carrier and Medicinal Composition GALK1, GALE, UGGT1 KIF11 3644/4885DUT 138/4885TK2 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.